Corabotase, Ipsen’s investigational recombinant neuroinhibitor, will be featured at SCALE 2026 with Phase II LANTIC data in glabellar lines and broader facial aesthetic development plans.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
Ipsen will present Phase II data from the LANTIC trial evaluating corabotase (IPN10200) for moderate to severe glabellar lines at the SCALE 2026 symposium on May 16, 2026. Recognized as the first molecule in a newly designated therapeutic class, this investigational recombinant neuroinhibitor is under study for three upper facial aesthetic indications: glabellar lines, forehead lines, and lateral canthal lines.
Ipsen reported positive Phase II topline results from LANTIC in September 2025, demonstrating rapid onset and sustained duration of effect in glabellar lines. The study enrolled 727 participants across dose-escalation and dose-finding stages, comparing corabotase to placebo and Dysport. Proof-of-concept data for forehead and lateral canthal lines are expected later in 2026.
Christelle Huguet, PhD, Executive Vice President and Head of Research and Development at Ipsen, stated: “Corabotase was engineered using recombinant protein technology and our proprietary manufacturing capabilities to combine an active catalytic domain with an affinity-enhanced binding domain. Its recognition as a new therapeutic class underscores its scientific differentiation and Ipsen’s neuroscience expertise.”
Designed to enhance receptor affinity, cellular uptake, and resistance to degradation, corabotase aims to prolong neurotransmitter inhibition and reduce muscle activity for extended effects. Step 3 of LANTIC generated proof-of-concept for glabellar lines in 183 patients; ongoing Stages 2 and 3 evaluate all three indications within Ipsen’s broader corabotase program.
Reference
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
About the Writer
Mahathi Palivela (LinkedIn) is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.